Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Fatigue –severity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Adverse events ( · people with a primary brain tumour
It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with a primary brain tumour
2 findings from 1 review
Cognition Trail Making Test A · people with a primary brain tumour
1 finding from 1 review
Cognition Trail Making Test B · people with a primary brain tumour
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Brivaracetam probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in treatment withdrawal compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).
1 finding from 1 review
Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life immediately after the intervention · people with Parkinson's disease
1 finding from 1 review
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Economic outcomes · people with Parkinson's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to lower rate of falls (falls per person‐year) compared with placebo (low certainty).
1 finding from 1 review
Number of people who experienced one or more falls · people with Parkinson's disease
1 finding from 1 review
Number of people sustaining one or more fall‐related fractures · people with Parkinson's disease
1 finding from 1 review
Pain resolution · people with SCD
1 finding from 1 review
Frequency of pain crises in the · people with SCD
Inhaled nitric oxide showed no clear difference in frequency of pain crises in the compared with placebo (low certainty).
2 findings from 1 review
Adverse events · people with SCD
1 finding from 1 review